The Safety and Immunogenicity of Acellular Pertussis Vaccine in Bone Marrow Transplant Recipients

Q

Queen Elizabeth II Health Sciences Centre

Status and phase

Unknown
Phase 4

Conditions

Pertussis

Treatments

Biological: Tetanus and Diphtheria Toxoids Adsorbed Combined with Acellular Pertussis (Adacel)

Study type

Interventional

Funder types

Other

Identifiers

NCT00336115
qeii

Details and patient eligibility

About

The purpose of this study is to determine if pertussis (whooping cough) vaccine is safe and produces an appropriate immune response against pertussis in blood and marrow transplant patients.

Enrollment

10 estimated patients

Sex

All

Ages

18 to 64 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Aged 18-64
  • BMT at the QEII Health Sciences Centre
  • BMT within last 12 months
  • Able to read and write English language
  • Able to give consent

Exclusion criteria

  • Active infection
  • Active GVHD
  • Recent IVIG
  • Allergy to components of vaccine
  • Diphtheria or tetanus vaccination within 18 months

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems